IP Library Granted Patent US 10,905,765
Granted Patent B2
US 10,905,765 · App. 14/926,707 · Granted Feb 2, 2021

Medical organogel processes and compositions

Inventors: Peter Jarrett (Lexington, MA); Rami El-Hayek (Norwood, MA); Amarpreet S. Sawhney (Lexington, MA)
Assignee: Incept, LLC
A61K47/34A61K9/06A61K38/38C07K16/00A61K9/0051
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,905,765
App. No.
14/926,707
Granted
Feb 2, 2021
Kind
B2
Abstract

Serial-solvent biomaterials are described. Embodiments include materials made in an organic solvent that are stripped of the solvent and used in a patient, where they imbibe water and form a hydrogel. These materials are useful for, among other things, delivering therapeutic agents, tissue augmentation, and radiological marking.

Claims (19)

1. A biomaterial for controlled release of a therapeutic water soluble biologic comprising

a pharmaceutically acceptable xerogel and

solid particles having a diameter from 1 μm to 30 μm and consisting essentially of the therapeutic water soluble biologic and a water soluble sugar stabilizing the therapeutic water soluble biologic,

with the particles being dispersed in the xerogel, with the xerogel being a hydrogel when exposed to water.

2. The biomaterial of claim 1 wherein the xerogel comprises covalently crosslinked hydrophilic polymers.

3. The biomaterial of claim 1 wherein the therapeutic water soluble biologic is a protein having a secondary and/or tertiary structure.

4. The biomaterial of claim 1 wherein the therapeutic water soluble biologic remains substantially in the solid phase when the hydrogel is formed and the therapeutic water soluble biologic slowly dissolves over a period of time when the hydrogel is exposed to physiological solution in vivo in a mammal.

5. The biomaterial of claim 1 wherein the xerogel consists essentially of covalently crosslinked hydrophilic polymers.

6. The biomaterial of claim 1 wherein the xerogel, when hydrated in water, is biodegradable by spontaneous hydrolysis of hydrolytically degradable linkages chosen from the group consisting of esters, carbonates, anhydrides and orthocarbonates.

7. The biomaterial of claim 1 wherein the xerogel is a chemical reaction product of a first precursor comprising a first functional group and a second precursor comprising a second functional group, with the first functional group and the second functional group reacted to form covalent bonds.

8. The biomaterial of claim 1 wherein the therapeutic water soluble biologic is a protein or is an oligopeptide having a molecular weight of no more than 5000 Daltons as measured by number weight average.

9. The biomaterial of claim 1 wherein the xerogel is free of hydrophobic materials.

10. A punctal plug comprising the biomaterial of claim 1 .

11. A method of controlled release of a therapeutic water soluble biologic comprising placing the biomaterial of claim 1 in contact with a tissue of a patient.

12. The method of claim 11 , wherein the tissue comprises a structure selected from the group consisting of an intraperitoneal space, a muscle, a dermis, an epidermis, a natural lumen or void, an abdominal cavity, a prostate, a rectum, and a vasculature.

13. The method of claim 11 wherein the tissue is an eye.

14. The method of claim 11 wherein the tissue is an anterior chamber of an eye, a posterior chamber of an eye, or a vitreous of an eye.

15. The method of claim 11 wherein the tissue is a punctum of an eye.

16. The method of claim 11 wherein the water soluble sugar comprises sucrose or trehalose.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Aug 4, 2023
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: OCULAR THERAPEUTIX, INC.
Reel/Frame 064497/0294 →
SECURITY INTEREST Recorded Aug 2, 2023
From: OCULAR THERAPEUTIX, INC.
To: BARINGS FINANCE LLC, AS AGENT
Reel/Frame 064476/0368 →
AMENDED AND RESTATED SECURITY INTEREST Recorded Jun 4, 2021
From: OCULAR THERAPEUTIX, INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 057254/0290 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2020
From: EL-HAYEK, RAMI; JARRETT, PETER; SAWHNEY, AMARPREET S.
To: INCEPT, LLC
Reel/Frame 053504/0993 →
SECURITY INTEREST Recorded Dec 21, 2018
From: OCULAR THERAPEUTIX, INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 047845/0171 →
Continuity (3)
Division 13705808 · Dec 5, 2012
Provisional Application 61566768 · Dec 5, 2011
Related Publication 20160045602A1 · Feb 18, 2016
Cited By (6)
US 12,310,890 US 12,329,853 US 12,357,565 US 12,453,724 US 12,678,400 US 12,678,401